All In Biotech

Free tool

FAERS Monitor: Caspofungin Acetate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206110 or its brand name (Caspofungin Acetate, Caspofungin Acetate). Reports on generic versions are filed under their own applications.

Reports

1,586

Serious

1,522

96% of reports

Hospitalization

617

Death reported

520

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective372
  • off label use99
  • multiple organ dysfunction syndrome91
  • septic shock74
  • death66
  • systemic candida65
  • drug resistance63
  • pneumonia63
  • product use in unapproved indication63
  • pyrexia62
  • febrile neutropenia58
  • acute kidney injury56
  • pathogen resistance56
  • sepsis56
  • drug interaction55

Reports by year received

View as table
YearReports
20044
200515
200610
200723
200815
200928
201042
201162
201251
201334
201437
201575
201650
201783
2018147
2019145
2020104
202189
2022110
202399
2024132
2025127
2026104

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,573 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
systemic candidaSignal65352.5276.921,852
pathogen resistanceSignal5682.063.34,374
multiple organ dysfunction syndromeSignal9142.735.03,661
drug resistanceSignal6332.625.61,896
septic shockSignal7422.618.11,506
febrile neutropeniaSignal5811.69.0553
sepsisSignal566.75.1265
acute kidney injurySignal564.93.8169
drug interactionSignal554.63.5152
drug ineffectiveSignal3723.73.4795
product use in unapproved indicationSignal633.42.6104
pneumoniaSignal632.62.060
pyrexiaSignal622.41.949
off label use991.51.217
death661.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.